medigraphic.com
ISSN 1029-3043 (Electronic)

2017, Number 3

<< Back Next >>

Medicentro 2017; 21 (3)

Properties of interferons and their antitumor action

González SN, Armada EZ, Llópiz CL

Language: Spanish
References: 27
Page: 192-198
PDF size: 351.88 Kb.


ABSTRACT

Introduction: In the Center for Genetic Engineering and Biotechnology, Havana, Cuba, after carrying out several in vitro studies to interferons, there was obtained a pharmaceutical formulation, named HeberPAG, containing a mixture of human alpha and gamma interferons of synergistic antiproliferative activity, with effect over the growth of some tumor cell lines (epidermoid carcinoma of the larynx, non-small-cell lung cancer, primary cultures of basal cell carcinoma and others). There have been proved other properties such as angiogenesis inhibition, apoptosis stimulation and immune-modulation, which make them widely used in oncologic diseases. It was subjected to preclinical tests which identified it as a safe product to be used in humans and clinical studies where it is proved its intratumoral, perilesional or both applications, with satisfactory results and adverse effects of low intensity. Formulation was optimized and CIGB-128-A was obtained with a higher biological potency than interferons separately.
Objective: to study the interferons more deeply.
Methods: bibliographic search was made from September to November, 2016. The 90 % of the selected articles were published in the last five years.
Conclusions: there was achieved with CIGB-128-A an equal or greater response than with HeberPAG in the shortest possible time, which will favor the therapy of cancer patients, susceptible to be treated with this product.


REFERENCES

  1. Bello-Álvarez C, Vázquez-Blomquist D, Miranda J, García Y, Novoa LI, Palenzuela D, et al. Regulation by IFN-α/IFN-γ co-formulation (HerberPAG®) of genes involved in interferon-STAT-pathways and apoptosis in U87MG. Curr Top Med Chem [internet]. 2014 [citado 10 ene. 2015];14(3):[aprox. 8 p.]. Disponible en: www.ncbi.nlm.nih.gov/pubmed/24304312

  2. Bello-Alvarez C. Quantification of mRNA in malignant glioma (U-87 cell line) in vitro model treated with the combination of interferon alpha2b and gamma IFNs [tesis]. Havana University: CIGB; 2011.

  3. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, John D. Hainsworthet JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med [internet]. 2012 [citado 10 ene. 2015];366:[aprox. 9 p.]. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1113713

  4. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Pérez S, López-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer [internet]. 2009 Jul. 30 [citado 11 abr. 2015];9:[aprox. 13 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/

  5. Bello-Rivero I, García-Vega Y, Valenzuela-Silva C, Bello-Alvarez C, Vázquez-Blomquist D, López-Saura P, et al. Development of a new formulation of interferons (HEBERPAG) for BCC treatment, J Cancer Res Ther [internet]. 2013 Dec. [citado 11 abr. 2015];1(10):[aprox. 9 p.]. Disponible en: http://www.nobleresearch.org/Doi/10.14312/2052-4994.2013-36

  6. Garcia-Vega Y, Anasagasti-Angulo L, Valenzuela-Silva C, Navarro-Mestre M, Maribeth-Ordoñez S, Acosta-Medina D, et al. Retrospective Study of Periocular non melanoma skin cancer treated with the combination of IFN alpha 2b and gamma (HeberPAG). J Clin Exp Ophthalmol [internet]. 2013 [citado 11 abr. 2015];6:[aprox. 10 p.]. Disponible en: https://www.omicsonline.org/open-access/retrospective-study-of-periocular-non-melanoma-skin-cancer-treated-with-thecombination-of-ifn-alpha2b-and-gamma-heberpag-2155-9570-1000478.php?aid=629437. Vázquez-Blomquist D, Fernández JR, Miranda J, Bello C, Silva JA. Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG. Mol Biol Rep. 2012;39:11167-75.

  7. Rudin CM. Vismodegib. Clin Cancer Res. 2012;18:3218-22.

  8. García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, D Tuero-Iglesias Á, et al. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG(R)) in patients with mycosis fungoides: an open-labe trial. BMC Pharmacol Toxicol [internet]. 2012 Dec. 28 [citado 11 abr. 2015];13:[aprox. 10 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633053/

  9. Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol [internet]. 2013 Nov. 29 [citado 17 abr. 2015];133:[aprox. 6 p.]. Disponible en: http://ac.els-cdn.com/S0022202X15361698/1-s2.0-S0022202X15361698-main.pdf?_tid=4c6fa9f8-4f8c-11e7-afc2-00000aacb361&acdnat=1497285145_95d925037b93939e2e6906ed54d0b46b

  10. Eisemann N, Waldmann A, Katalinic A. Epidemiology of Breast Cancer – Current Figures and Trends. Geburtshilfe Frauenheilkd [internet]. 2013 Feb. [citado 17 abr. 2015];73(2):[aprox. 6 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858992/

  11. Jiménez Barbán Y, Vega Pupo C, Vila Pinillo D, Fernández Ychaso G, Arias Núñez V, Bello Rivero I. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cubana Oftalmol [internet]. 2014 [citado 10 dic. 2016];27(3):[aprox. 8 p.]. Disponible en: http://scielo.sld.cu/pdf/oft/v27n3/oft14314.pdf

  12. US Food and Drug Administration. Product-Specific Guidances for Generic Drug Development: Active Ingredients starting with 'V' [internet]. United States of America: FDA; 2012 [citado 11 abr. 2015]. Disponible en: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm081338.htm

  13. Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. J Skin Cancer [internet]. 2011 [citado 19 jul. 2015];2011(2011):[aprox. 7 p.]. Disponible en: https://www.hindawi.com/journals/jsc/2011/380371/

  14. Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Drug Discov. 2012;11:437-8.

  15. Eiseman N, Waldmann A, Geller AC, Weinstock MA, Greinert R, Breitbartn EW, et al. Non- Melanoma Skin Cancer Incidence and Impact of Skin Cancer Screening on Incidence. J Invest Dermatol [internet]. 2014 [citado 10 ene. 2015];134(1):[aprox. 8 p.]. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022202X15364460

  16. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol [internet]. 2012 Feb. [citado 10 ene. 2015];66(2):[aprox. 11 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22074699

  17. Katalinic A, Waldmann A, Weinstock MA. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;118:5395-402.

  18. Kraywinkel K, Wolf U, Katalinic A. Malignant neoplasms of the skin-epidemiology and screening programme. Umwelt und Mensch Informations dienst (UMID). UV-Strahlung. 2012; 2(Themenheft):30-4.

  19. Hayano SM, Whipple KM, Korn BS, Kikkawa DO. Principles of Periocular Reconstruction following Excision of Cutaneous Malignancy. J Skin Cancer [internet]. 2012 [citado 10 ene. 2015];2012(2012):[aprox. 6 p.]. Disponible en: https://www.hindawi.com/journals/jsc/2012/438502/

  20. The Surgeon General's Call to Action to Prevent Skin Cancer. Skin Cancer as a Major Public Health Problem [internet]. Washington (DC): US Department of Health and Human Services; 2014 [citado 12 abr. 2015]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK247164/

  21. Samarasinghe V, Madan V. Non- melanoma skin cancer. J Cutan Aesthet Surg [internet]. 2012 Mar. 27 [citado 4 sep. 2015];5(1):[aprox. 8 p.]. Disponible en: http://www.jcasonline.com/article.asp?issn=0974-2077;year=2012;volume=5;issue=1;spage=3;epage=10;aulast=Samarasinghe

  22. Langagergaard V, Garne JP, Vejborg I. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening. Clin Epidemiol. 2013;5:81-8.

  23. American Academy of Dermatology. Skin Cancers [internet]. United States of America: AAD; 2011 [citado 12 abr. 2015]. Disponible en: https://www.aad.org/media/stats/conditions/skin-cancer

  24. Waldmann A, Nolte S, Weinstock MA. Skin cancer screening participation and impact on melanoma incidence in Germany—an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012;106:970-4.

  25. Schnoor M, Waldmann A, Eberle A. Colorectal cancer incidence in Germany: stage-shift 6 years after implementation of a colonoscopy screening program. Cancer Epidemiol. 2012;36:417-20.

  26. Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing; 2013.

  27. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol [internet]. 2012 May [citado 17 abr. 2015];166(5):[aprox. 12 p.]. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2012.10830.x/full




2020     |     www.medigraphic.com